Immunovant Financial Statements
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
30.47+0.21 (+0.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunovant revenue and earnings
Immunovant reported a net loss of $505.6 million, compared with a loss of $413.8 million a year earlier. Diluted earnings per share came in at -$2.77.
Summary generated from market data by MetaCap's automated system. Methodology
Immunovant income statement (annual)
| Fiscal year (USD) | FY 20262026-03-31 | FY 20252025-03-31 | FY 20242024-03-31 | FY 20232023-03-31 | FY 20222022-03-31 | FY 20202021-03-31 | FY 20192020-03-31 | FY 20192019-03-31 |
|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 532.90M | 438.15M | 282.71M | 218.28M | 156.03M | 108.12M | 66.08M | 28.43M |
| Research & Development | 456.66M | 360.92M | 212.93M | 160.26M | 101.81M | 68.60M | 47.93M | 25.73M |
| Interest Expense | — | — | — | — | — | 0 | 625.00K | — |
| Other Income (Expense) | 2.18M | 471.00K | -1.01M | -253.00K | -781.00K | 328.00K | 412.00K | -155.00K |
| Pretax Income | -505.39M | -412.95M | -258.77M | -210.95M | -156.81M | -107.79M | -66.29M | -28.58M |
| Income Tax | 215.00K | 891.00K | 567.00K | 9.00K | -84.00K | -358.00K | 97.00K | 19.00K |
| Net Income | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M | -28.60M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | -1.29 |
| EPS (Diluted) | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | -1.29 |
| Shares Outstanding (Basic) | 182.42M | 151.57M | 138.10M | 123.08M | 109.68M | 87.76M | 43.20M | 22.17M |
| Shares Outstanding (Diluted) | 182.42M | 151.57M | 138.10M | 123.08M | 109.68M | 87.76M | 43.20M | 22.17M |
This table shows 8 annual periods of Immunovant's income statement, from FY 2026 back to FY 2019, across 11 line items including operating expenses, research & development, interest expense. Values in USD; B = billions, M = millions. Fiscal periods follow IMVT's reporting calendar. What is a income statement?